Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4(+) cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4(+) cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period.